← Eichor
Condition: Well Differentiated Liposarcoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Well Differentiated Liposarcoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Diffe
Phase 3 · 257 location(s) · National Cancer Institute (NCI) · NCT06422806Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas
NA · 1 location(s) · Institut du Cancer de Montpellier - Val d'Aurelle · NCT04224064NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and S
Phase 1/Phase 2 · 7 location(s) · St. Jude Children's Research Hospital · NCT06239272A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid
Phase 1/Phase 2 · 16 location(s) · Shanghai Pharmaceuticals Holding Co., Ltd · NCT05944224A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
Phase 1/Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06843967
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.